Studies in patients with myelodysplastic neoplasms (MDS) demonstrated that patients carrying an SF3B1 mutation have a significantly better prognosis compared with patients without SF3B1 mutations (72–74). The gene discussed is SF3B1; the disease is myelodysplastic syndrome.